Biorce Raises $52.5M Series A for AI Clinical Trial Innovation

Biorce, a Barcelona-based innovator in health AI, has successfully closed a substantial $52.5 million Series A funding round. This significant capital infusion is earmarked to fuel the company's aggressive international expansion and further its mission to revolutionize clinical trial design and execution through advanced artificial intelligence. The financing round saw robust participation from new investor DST Global Partners, alongside increased commitments from existing backers Norrsken VC and YZR Capital. Additional support came from Mustard Seed Maze and Endeavor Catalyst, underscoring broad investor confidence.

This funding achievement marks a significant milestone, representing the largest Series A round ever recorded within the Iberian healthtech and AI sectors. The round also attracted notable angel investors, including prominent figures like Nik Storonsky (CEO of Revolut), Arthur Mensch (co-founder and CEO of Mistral AI), Paulo Rosado (founder of OutSystems), Albert Nieto (founder of Seedtag), Stef Van Grieken (co-founder of Cradle), Alex Berriche (founder of Fleet), and Phil Teixeira da Mota. This collective backing highlights Biorce's rapid ascent and its established credibility in transforming clinical research.

The company's trajectory has been marked by impressive growth, with this Series A following a series of successful seed investments totaling €8.5 million over the past year. This latest funding brings Biorce's total capital raised to over $60 million. The company concluded the previous year significantly exceeding its revenue targets by approximately 200%, demonstrating strong market traction and operational efficiency.

The clinical trials management market is a colossal segment, estimated to generate over $120 billion in global annual spend. Biorce is strategically positioning its AI platform, centered around its core technology 'Aika', to establish a new industry benchmark for trial design and operational management. Traditional clinical trial processes are often plagued by inefficiencies; for instance, protocol amendments can halt patient recruitment for an average of six weeks and incur costs ranging from €500,000 to €1 million per instance, leading to billions in annual industry-wide expenses. A primary driver of these delays is the difficulty many teams face in providing clear, data-backed justifications for design decisions to regulatory bodies like the FDA and EMA.

'Aika' is engineered to address these critical pain points. This sophisticated, data-driven solution is designed to proactively identify potential risks, minimize errors, and eliminate costly protocol amendments, potentially accelerating the development of new therapies by up to 50%. Leveraging a vast dataset encompassing over 1 million clinical trials, the platform empowers pharmaceutical companies, biotech firms, and Contract Research Organizations (CROs) to design more effective trials with greater speed, all while upholding scientific integrity and patient safety.

Pedro Coelho, CEO of Biorce, emphasized the significance of the funding, stating, "This $52.5 million round reflects both the scale of the problem we are addressing and the market’s confidence in our vision. Clinical trial delays and inefficiencies cost time, money, and ultimately lives. Our mission is to make trials faster, more reliable, and more accessible, so patients can benefit from new treatments sooner." The company is also preparing to establish a development and R&D hub in Austin, Texas, to bolster its U.S. presence and foster closer ties with leading life science ecosystems. Furthermore, Biorce is relocating to expanded offices in Barcelona, formerly the headquarters of AstraZeneca in the city, to accommodate its growing team, which is projected to reach 250 employees by the end of 2026.